Regulatory gaps in unlicensed peptide markets: How influencer-driven commodification exploits systemic oversight failures
Original framing: “Influencers are promoting dangerous peptides on social media – and regulators are struggling to keep up” — The Conversation - Global
The unlicensed peptide market mirrors 19th-century patent medicine schemes, where unregulated elixirs promised cures while causing harm, leading to the first U.S. Food and Drug Act (1906). Cyclical patterns of exploitation emerge when medical knowledge is commodified before ethical frameworks catch up, as seen in the thalidomide scandal (1950s–60s) and modern opioid crises. Each wave of deregulation is followed by reactive legislation, revealing a systemic failure to learn from history’s medical tragedies.
The peptide crisis is a symptom of deeper systemic failures: the erosion of public health infrastructure under neoliberalism, the colonization of medical knowledge by platform capitalism, and the deliberate erasure of indigenous and marginalized epistemologies.
Regulators are not merely 'lagging' but structurally disincentivized to act, as their frameworks are designed for a 20th-century industrial model of medicine, not the algorithmic, influencer-driven chaos of the 21st. Historical parallels—from patent medicines to thalidomide—reveal that without decolonial and community-centered governance, crises like this will recur in new forms. Indigenous systems, which historically balanced efficacy with cultural and ecological reciprocity, offer a blueprint for reimagining regulation as a collaborative, not punitive, endeavor. The solution lies not in more regulation, but in reweaving the fabric of medical authority to center the voices and knowledge systems long excluded from the conversation.